Table 1.
Molecular characteristics of select novel antibody-drug conjugates.
| ADC | Target Antigen | Chemical Linker | Cytotoxic Compound | Development Status |
|---|---|---|---|---|
| Enfortumab vedotin | Nectin-4 | Protease-cleavable | MMAE | Approved for mUC |
| Sacituzumab govitecan | Trop-2 | Acid-labile | SN-38 | Phase II in mUC |
| Trastuzumab deruxtecan | HER2 | Protease-cleavable tetrapeptide | deruxtecan | Phase I |
| RC48 | HER2 | Cathepsin-cleavable | MMAE | Phase II mUC |
| Gemtuzumab ozogamicin | CD33 | Acid-cleavable hydrazone | calicheamicin | Approved for AML |
| Brentuximab vedotin | CD30 | Protease-cleavable | MMAE | Approved for lymphoma (HL, ALCL, PTCL) |
| Inotuzumab ozogamicin | CD22 | Acid-cleavable | calicheamicin | Approved for B-ALL |
| Polatuzumab vedotin | CD79b | Protease-cleavable | MMAE | Approved for DLBCL |
| Trastuzumab emtansine | HER2 | Non-cleavable thioether | emtansine | Approved for HER2+ breast cancer |